Accounting for center-level effects in multicenter randomized controlled trials

Author:

Islam ShofiqulORCID,Bangdiwala Shrikant I.

Abstract

AbstractInvestigators often conduct randomized controlled trials (RCTs) at multiple centers/sites when determining the effect of a treatment or an intervention. Diversifying recruitment across multiple institutions allows investigators to make recruitment go faster within a shorter timeframe and allows generalizing the study results across diverse populations. Despite having a common study protocol across multiple centers, the eligible participants may be heterogeneous, site policies and practices may vary, and the investigators’ experience, training, and expertise may also vary across sites. These factors may contribute to the heterogeneity in effect estimates across centers. As a result, we usually observe some degree of heterogeneity in effect estimates across centers, despite all centers following the same study protocol. During the analysis of such a trial, investigators typically ignore center effects, but some have suggested considering centers as fixed or random effects in the model. It is not clear how considering the effects of centers, either as fixed or random effects, impacts the test of the primary hypothesis. In this article, we first review the practice of accounting for center effects in the analyses of published RCTs and illustrate the extent of heterogeneity observed in a few preexisting multicenter RCTs. To determine the impact of heterogeneity on the test of a primary hypothesis of an RCT, we considered continuous and binary outcomes and the corresponding appropriate model, namely, a simple linear regression model for a continuous outcome and a logistic regression model for the binary outcome. For each model type, we considered three methods: (a) ignore the center effect, (b) account for centers as fixed effects, or (c) account for centers as random effects. Based on simulation studies of these models, we then examine whether considering the center as a fixed or random effect in the model helps to preserve or reduce the type I and type II error rates during the analysis phase of an RCT. Finally, we outline the threshold at which center-level effects are negligible and thus negligible and provide recommendations on when it may be necessary to account for center effects during the analyses of multicenter randomized controlled trials.

Funder

Population Health Research Institute

Publisher

Springer Science and Business Media LLC

Reference14 articles.

1. Čulić V. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 2017;376(9):896. https://doi.org/10.1056/NEJMc1615918.

2. John W. Eikelboom, M.B., B.S., Stuart J. Connolly, M.D., Jackie Bosch, Ph.D., Gilles R. Dagenais, M.D., Robert G. Hart, M.D., Olga Shestakovska, M.Sc., Rafael Diaz, M.D., Marco Alings, Ph.D., Eva M. Lonn, M.D., Sonia S. Anand, M.D., Petr Widimsky, M.D., M, for the C. I. (2017). Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine, 377(14), 1319–1330. https://doi.org/10.1056/NEJMoa1709118.

3. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia N, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–9. https://doi.org/10.1056/NEJMoa1215340.

4. StephenSenn; Lewis, R. J. J. JAMA guide to statistics and methods: Treatment effects in multicenter randomized clinical trials. JAMA - Journal of the American Medical Association. 2019;321(12):1211–2. https://doi.org/10.1001/jama.2018.4853.

5. McGillion, M. H., Parlow, J., Borges, F. K., Marcucci, M., Jacka, M., Adili, A., Lalu, M. M., Ouellette, C., Bird, M., Ofori, S., Roshanov, P. S., Patel, A., Yang, H., O’Leary, S., Tandon, V., Hamilton, G. M., Mrkobrada, M., Conen, D., Harvey, V., … Devereaux, P. J. (2021). Postdischarge after surgery Virtual Care with Remote Automated Monitoring-1 (PVC-RAM-1) technology versus standard care: randomized controlled trial. The BMJ, 374: 1-11. https://doi.org/10.1136/bmj.n2209.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3